RESUMEN
INTRODUCTION: The incidence of rhabdomyolysis associated with statin therapy is underestimated, especially when they are coprescribed with other drugs. CASE REPORT: We report a 68-year-old man who presented with rhabdomyolysis causing muscle weakness that occurred seven months after fusidic acid was coprescribed with atorvastatin. A literature review identified eight additional cases of rhabdomyolysis with fusidic acid and atorvastatin and six with fusidic acid and simvastatin. The risk of rhabdomyolysis associated with statin therapy is dependent of the extent to which an individual statin is metabolized by P450 3A4 isoenzyme and to the degree of inhibition of this isoenzyme activity by some antimicrobial. CONCLUSION: Our case report highlights the importance of the close monitoring of patients on statins, especially when new drugs are started or if patients become symptomatic, with testing for occurrence of muscle weakness and creatine kinase serum level.
Asunto(s)
Antibacterianos/efectos adversos , Ácido Fusídico/efectos adversos , Ácidos Heptanoicos/efectos adversos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Pirroles/efectos adversos , Rabdomiólisis/inducido químicamente , Anciano , Antibacterianos/administración & dosificación , Atorvastatina , Creatina Quinasa/sangre , Ácido Fusídico/administración & dosificación , Ácidos Heptanoicos/administración & dosificación , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Masculino , Debilidad Muscular/inducido químicamente , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Pirroles/administración & dosificación , Rabdomiólisis/sangre , Infecciones Estafilocócicas/tratamiento farmacológicoRESUMEN
Echinocandins are a new class of antifungal agents with a specific mechanism of action. These drugs inhibit the enzyme 1,3ß-D-glucan synthetase which is responsible for the formation of 1,3ß-D-glucan, an essential fungal cell wall component. They have a good activity against Candida species and Aspergillus. Three agents are available at the present time or under development : caspofungin, micafungin and anidulafungin. These drugs require intravenous administration. Efficacy, safety, rare drugs interactions and specificity of action are advantages for therapy of invasive fungal infections. In France, micafungin and caspofungin are approved for a pediatric use.
Asunto(s)
Antifúngicos/uso terapéutico , Equinocandinas/uso terapéutico , Micosis/tratamiento farmacológico , Anidulafungina , Antifúngicos/farmacología , Aspergilosis/tratamiento farmacológico , Aspergillus/efectos de los fármacos , Candidiasis Invasiva/tratamiento farmacológico , Caspofungina , Niño , Equinocandinas/farmacología , Medicina Basada en la Evidencia , Humanos , Inyecciones Intravenosas , Lipopéptidos/uso terapéutico , Micafungina , Resultado del TratamientoAsunto(s)
Antifúngicos/uso terapéutico , Antifúngicos/administración & dosificación , Niño , Preescolar , Humanos , LactanteRESUMEN
AIM OF STUDY: In order to optimise the use of new forms of Amphotericine B (Ampho B), a decisional tree was created at the end of 2001 in the paediatric hemato-oncology unit for the empirical antifungal treatment in febrile neutropenic children: the standard remained conventional Ampho B and Abelcet was proposed in case of antecedent or occurrence of a deterioration of the renal function (DRF). In order to validate the place of Abelcet we initiated a retrospective study over year 2002. RESULTS: 21 treatments were begun in 14 children for a median duration of 8 days (1-48 days). Three kind of indications were found: DRF antecedent (10 episodes: A group), DRF occurrence during a treatment with conventional Ampho B (7 episodes: B group), age lower than 1 year (3 episodes). 81% of the children were thus treated according to the decisional tree. The clinical tolerance was good in 90% of the cases, with a premedication in half of the cases. The study of the renal function showed a good renal tolerance for 6 episodes out of 9 evaluable in A group, 3 resolutions and 2 stabilisation of the renal failure for the 5 evaluable episodes of the B group. Seven to ten days of treatment by Abelcet were necessary to obtain the renal failure resolved. CONCLUSION: This study confirms the interest of Abelcet in the empirical antifungal treatment in febrile neutropenic children and specially in children having antecedents of DRF related or not to a treatment with conventional Ampho B.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Neutropenia/tratamiento farmacológico , Fosfatidilcolinas/uso terapéutico , Fosfatidilgliceroles/uso terapéutico , Niño , Creatinina/sangre , Combinación de Medicamentos , Fiebre , Neoplasias Hematológicas/complicaciones , Humanos , Pruebas de Función Renal , Neutropenia/etiología , Neutropenia/microbiología , Estudios RetrospectivosRESUMEN
GOALS OF WORK: We evaluated piperacillin-tazobactam in association with netilmicin (TN) in the early empirical treatment of neutropenic children, as data are limited in number. PATIENTS AND METHOD: In 1996, an observational study was initiated to assess the efficacy and safety of this association, with a glycopeptide (TNG) if needed. The impact on the bacterial ecology of our unit was also observed. Children were treated for hematological malignancy or solid tumor between September 1996 and December 1998 and presented a febrile neutropenia. RESULTS: There were 148 evaluable febrile neutropenic episodes in 104 patients. Median age was 7 years, 55% of the episodes were fever of unknown origin, 22% were clinically documented and 23% microbiologically documented (27 bacteriemia). A glycopeptide was added in 67 episodes. The initial unmodified treatment was successful in 114 episodes (77%): 75/81 episodes in the TN group and 39/67 in the TNG group. For successful episodes, median treatment duration was 6 days. There were 22 febrile recurrences. These patients, as well as initial failures, always responded to a second-line treatment. One child was considered a failure because he developed a skin rash probably due to piperacillin-tazobactam and required another beta-lactamase. CONCLUSION: This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenic children. It allowed us to maintain the bacterial ecology of our unit.
Asunto(s)
Antibacterianos/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Fiebre/inducido químicamente , Fiebre/tratamiento farmacológico , Netilmicina/uso terapéutico , Neutropenia/inducido químicamente , Neutropenia/tratamiento farmacológico , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/uso terapéutico , Adolescente , Antibacterianos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Niño , Preescolar , Quimioterapia Combinada , Inhibidores Enzimáticos/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Netilmicina/administración & dosificación , Ácido Penicilánico/administración & dosificación , Piperacilina , Recurrencia , Tazobactam , Resultado del TratamientoRESUMEN
Incidence of severe candidal infections is rapidly increasing since 15 years and is becoming a major concern in onco-hematology practice, especially due to its poor prognosis in neutropenic patients. Diagnosis of candidemia is suspected in case of persistent fever resistant to a large antibiotherapy and requires to search for secondary locations as cutaneous and hepatosplenic candidal infection. Improvement of yeasts detection in blood culture bottles with specific medium is now helpful but use of specific immunoserodiagnosis or PCR methods is at this point unuseful. Fluconazole and Amphotericine B remain the recommended treatments for candidemia. Indications for "new antifongal drugs" are still limited regarding their high cost and the limited clinical studies.